HYTN releases cannabis products for sale in Germany

Executive Summary

• HYTN Innovations Inc. successfully released its wholesale cannabis products into the German market, completing all required import, quality control, and market release procedures for Germany's regulated medical cannabis sector.
• Following the successful release, the company has accepted a reorder for additional wholesale product, signaling initial commercial traction and validating its GMP platform.
• The company views this milestone as validation of its strategy to expand pharmaceutical-grade cannabis sales into highly regulated international markets, supporting its goal of building recurring international revenue channels.

Key Details

• Market Entry: Successful release of wholesale cannabis products into Germany's regulated medical cannabis market.
• Compliance: Completion of all required import, quality control, and market release procedures specific to Germany.
• Commercial Activity: Acceptance of a reorder for additional wholesale product immediately following the initial release.
• Strategic Context: This event builds on a previously announced strategic supply framework for Germany.
• Validation: The release validates that HYTN's Good Manufacturing Practice (GMP) platform meets the stringent requirements of a tightly regulated international market.

Notable Quotes

• "The successful release of product into the German market is a significant commercial milestone... It validates that our GMP platform meets the stringent requirements of one of the world's most tightly regulated medical cannabis markets. The acceptance of a reorder is a positive indicator as we continue toward building recurring international revenue channels." — Elliot McKerr, Chief Executive Officer